about
Semaphorin 3A in Ankylosing Spondylitis.The pathogenesis of systemic lupus erythematosus - From the viewpoint of oxidative stress and mitochondrial dysfunction.Increased 8-hydroxy-2'-deoxyguanosine in plasma and decreased mRNA expression of human 8-oxoguanine DNA glycosylase 1, anti-oxidant enzymes, mitochondrial biogenesis-related proteins and glycolytic enzymes in leucocytes in patients with systemic lupSurvival analysis in systemic lupus erythematosus patients on maintenance dialysis: a nationwide population-based study in Taiwan.Methotrexate-associated lymphoproliferative disease with multiple pulmonary nodules in a patient with rheumatoid arthritis.Alterations of oxygen consumption and extracellular acidification rates by glutamine in PBMCs of SLE patients.The current status and unmet needs in the management of psoriatic arthritis: Viewpoint from physicians in Taiwan.Suppressor of cytokine signaling (SOCS) 1 is down-regulated in renal transplant recipients with rejection.Autoantibody and biopsy grading are associated with expression of ICAM-1, MMP-3, and TRAIL in salivary gland mononuclear cells of Chinese patients with Sjogren's syndrome.Janus kinase-1 and 3 in ankylosing spondylitis.IgG4-related disease coexisting with autoimmune haemolytic anaemia.Hemophagocytic Lymphohistiocytosis in DermatomyositisAnti-agalactosyl IgG antibody in ankylosing spondylitis and psoriatic arthritisA large pseudoaneurysm of the superficial femoral artery in a patient with SLE with Salmonella group D infectionTelbivudine associated mitochondrial myopathyCytomegaloviral or Pneumocystis Jiroveci Pneumonia Increases Mortality in Systemic Lupus Erythematosus Patients with Pulmonary Hemorrhage: Evidence from Bronchoalveolar Lavage FluidLow but Long-lasting Risk of Reversal of Seroconversion in Patients With Rheumatoid Arthritis Receiving Immunosuppressive TherapyCross-Talk between Mitochondrial Dysfunction-Provoked Oxidative Stress and Aberrant Noncoding RNA Expression in the Pathogenesis and Pathophysiology of SLESAPHO syndrome with enthesopathyRenal transplantation delays major adverse cardiac events (MACEs) in patients with end-stage renal disease: A nationwide population-based studyReal-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: A single-center experience in TaiwanRisk of severe herpes simplex virus infection in systemic lupus erythematosus: analysis of epidemiology and risk factors analysis in TaiwanEfficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysisPathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis
P50
Q38665781-BC3934EF-B111-4A58-86E2-727D8C414A75Q38846911-989E4DB5-F98D-41AA-9350-275902AA6F0AQ42707894-4ED6BA10-D7CA-476A-A6B7-FBED61A11C3AQ44780985-608D5782-EF87-404C-9973-3393A246904BQ47570516-13F3BC0A-D8DE-46C2-8027-306B63370406Q47654575-74183316-8627-4BB6-8AE0-0BFB393FDC28Q47874051-EACBE2B0-8C4C-4265-B513-4A571B9E0316Q48048568-3D3F5C7A-0536-4C79-AB2B-ADF8609F4AE2Q51744240-AEDE5E79-1102-49B8-AE54-63B5300A0470Q52727102-1DB1F5B2-4363-4F7F-98C6-80FD22E7E891Q55607196-956287E9-A31C-4AF2-B491-D53BE38E6C9AQ61452045-08046C87-91F0-4B3D-B83D-00E993BCD779Q83189340-86908320-8B0F-46E6-9FD1-B4BD09FF4D47Q88112432-A34F12CC-4496-4BE3-B1C9-7C3BECC9C7A5Q88148420-BC606455-6D8D-4A1D-B8F5-3707B9B53B65Q90030590-31C719BA-4ED6-4953-A863-655C9A990BEDQ90602833-DC63AE80-B1EF-49FB-AE1A-5E0F721F33CEQ90850762-A04EEAC7-A8EF-438D-9034-9C3572CA2A04Q90928822-6DE16639-2758-4EDD-A251-06656CF14DBEQ91262720-224480EE-DE9E-4FD8-B9B5-39D7F46D4BABQ91565643-38408298-A8A9-46AB-919B-391DFE937574Q92898223-78EF97EF-0406-4E8A-AD8B-D6267500A7EEQ93166273-CC15BAD6-78CD-4E49-87D3-5A8D6D6D0EE9Q94459345-73AE3C96-0C49-499F-A3C0-E9C55AA969AC
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Chang-Youh Tsai
@ast
Chang-Youh Tsai
@en
Chang-Youh Tsai
@es
Chang-Youh Tsai
@nl
Chang-Youh Tsai
@sl
type
label
Chang-Youh Tsai
@ast
Chang-Youh Tsai
@en
Chang-Youh Tsai
@es
Chang-Youh Tsai
@nl
Chang-Youh Tsai
@sl
altLabel
CY Tsai
@en
prefLabel
Chang-Youh Tsai
@ast
Chang-Youh Tsai
@en
Chang-Youh Tsai
@es
Chang-Youh Tsai
@nl
Chang-Youh Tsai
@sl
P1053
G-1747-2013
P106
P31
P3829
P496
0000-0002-4154-4018
P569
2000-01-01T00:00:00Z